The therapeutic benefits of histone deacetylase (HDAC) inhibitors in multiple myeloma have been acknowledged for many years, but dose‑limiting toxicities have hindered their use. Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, talks on the latest research on HDAC inhibitors in myeloma and why they should still be considered a valuable drug class worth pursuing in this setting. Prof. Ocio shares ongoing investigations into improving tolerability and selectivity of HDAC inhibitors, as well as assessing their use for maintenance therapy and potentiation of immunotherapy. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Honoraria or consultancy fees from Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD and Mundipharma-EDO